San Antonio Breast Cancer Symposium (SABCS)

The addition of pembrolizumab to chemotherapy benefited previously untreated patients with triple-negative breast cancer, regardless of chemotherapy regimen.

The addition of adjuvant chemotherapy to endocrine therapy may not benefit certain postmenopausal women with node-positive, early-stage breast cancer.

Women who received silicone breast implants from Poly Implant Prothèse did not have an increased risk of breast cancer recurrence or early death, a retrospective study found.

Preclinical evidence suggests that stimulating the immune system may bypass MYC and improve the efficacy of immunotherapy in triple-negative breast cancer.

Long-term data showed that anastrozole and tamoxifen have similar efficacy in postmenopausal women with hormone receptor-positive DCIS, but toxicity profiles differed.

Results of the PENELOPE-B study do not support the addition of 1 year of palbociclib to endocrine therapy in HR+, HER2− disease, according to researchers.

The addition of abemaciclib to adjuvant endocrine therapy was found to delay invasive disease for patients with high-risk early breast cancer, but longer follow-up is needed.

Patients who received oral paclitaxel with encequidar had lower rates of neuropathy, but higher rates of neutropenia, anemia, and gastrointestinal adverse events.

Image-guided core-needle biopsy did not improve the predictive value of trimodality imaging after neoadjuvant therapy for patients with operable breast cancer.

Estrogen alone and estrogen plus progestin appeared to have “opposite effects” on risk of breast cancer and death among postmenopausal women.